ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans cut its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 3.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,991 shares of the medical instruments supplier’s stock after selling 600 shares during the quarter. Thrivent Financial for Lutherans owned about 0.07% of ICU Medical worth $2,018,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Innealta Capital LLC acquired a new position in shares of ICU Medical during the 2nd quarter worth approximately $32,000. Motco purchased a new position in ICU Medical during the first quarter worth approximately $29,000. GAMMA Investing LLC boosted its stake in ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 133 shares during the last quarter. EntryPoint Capital LLC grew its holdings in ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ICUI. KeyCorp boosted their price target on shares of ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and an average target price of $149.00.

Insiders Place Their Bets

In other news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $18,665,666.78. The disclosure for this sale can be found here. Insiders have sold 40,552 shares of company stock worth $6,679,322 over the last three months. Company insiders own 6.70% of the company’s stock.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $179.14 on Wednesday. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The company has a 50 day moving average price of $157.00 and a 200 day moving average price of $125.33. The stock has a market capitalization of $4.36 billion, a P/E ratio of -73.12 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.58 earnings per share. Equities research analysts forecast that ICU Medical, Inc. will post 3.76 EPS for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.